aTYR PHARMA INC — Director's Dealing 2023

Feb 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-02-03

Reporting Person: Shukla Sanjay (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-03	Common stock	M	10375	—	Acquired	61173	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-03	Restricted Stock Unit	$	M	10375	Disposed		Common Stock (10375)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.